Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864083 · ClinicalTrials.gov registry record · Early Phase 1
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT01864083: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01864083 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01864083, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or PEM can accurately measure your response to chemotherapy.
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)
- PROCEDURE Positron emission mammography (PEM) When available
- PROCEDURE MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-08-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864083
The ClinicalTrials.gov registry entry for NCT01864083 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT01864083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01864083 about?
NCT01864083 is a clinical study titled "FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients". This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or PEM can accurately measure your response to chemotherapy.
What is the current status of trial NCT01864083?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2013-05. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT01864083?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) (DRUG), Positron emission mammography (PEM) When available (PROCEDURE), MR (PROCEDURE).
Who is sponsoring clinical trial NCT01864083?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.